Salbutamol-Sulfate shortage — AU supply status & alternatives

Salbutamol-Sulfate

—

In shortage · Australia

SALBUTAMOL CIPLA salbutamol

In declared shortage · 🇦🇺 Australia

Critical shortage

Reading today’s signals…

✓ Can I substitute?

Yes — approved substitute available

TGA-approved overseas product

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Oct 2026

Sponsor est. via TGA — may differ by brand

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	Salbutamol-Sulfate
Brand names	SALBUTAMOL CIPLA salbutamol
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

✓

Section 19A approval in force

An overseas registered product has been approved for supply under Section 19A. See the website and search for the active ingredient: https://www.tga.gov.au/resources/section-19a-approvals.

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.